Catalyst Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Catalyst Pharmaceuticals, Inc.‘s stocks are currently a part of 205 hedge funds’ portfolios, which represents 68.42% of the total amount of its stocks outstanding. This makes up a total of 74.76M shares of Catalyst Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -1.37% or -1.03M shares fewer. As for the holding position changes, 30.73% (63) of current hedge fund investors increased the number of shares held, 28.78% (59) of current holders sold a part of the shares held, and 8.78% (18) closed the holdings completely. 59 hedge funds are new holders of Catalyst Pharmaceuticals, Inc. stock in Q3 2022, it is 28.78% of total holders.
Hedge funds holding Catalyst Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 105 |
|---|---|
| Q1 2018 | 98 |
| Q2 2018 | 98 |
| Q3 2018 | 96 |
| Q4 2018 | 86 |
| Q1 2019 | 88 |
| Q2 2019 | 101 |
| Q3 2019 | 117 |
| Q4 2019 | 130 |
| Q1 2020 | 131 |
| Q2 2020 | 140 |
| Q3 2020 | 141 |
| Q4 2020 | 133 |
| Q1 2021 | 133 |
| Q2 2021 | 138 |
| Q3 2021 | 140 |
| Q4 2021 | 164 |
| Q1 2022 | 182 |
| Q2 2022 | 182 |
| Q3 2022 | 205 |
Hedge funds changes in Catalyst Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 40 | 28 | 21 | 13 | 3 |
|---|---|---|---|---|---|
| Q1 2018 | 18 | 42 | 19 | 25 | -6 |
| Q2 2018 | 16 | 46 | 22 | 16 | -2 |
| Q3 2018 | 12 | 36 | 25 | 14 | 9 |
| Q4 2018 | 13 | 32 | 23 | 23 | -5 |
| Q1 2019 | 15 | 25 | 26 | 13 | 9 |
| Q2 2019 | 29 | 38 | 19 | 14 | 1 |
| Q3 2019 | 29 | 41 | 28 | 13 | 6 |
| Q4 2019 | 30 | 47 | 34 | 17 | 2 |
| Q1 2020 | 21 | 44 | 49 | 19 | -2 |
| Q2 2020 | 24 | 41 | 46 | 16 | 13 |
| Q3 2020 | 26 | 42 | 47 | 22 | 4 |
| Q4 2020 | 17 | 40 | 50 | 23 | 3 |
| Q1 2021 | 17 | 48 | 45 | 16 | 7 |
| Q2 2021 | 22 | 40 | 56 | 16 | 4 |
| Q3 2021 | 18 | 44 | 53 | 15 | 10 |
| Q4 2021 | 33 | 52 | 60 | 10 | 9 |
| Q1 2022 | 33 | 56 | 73 | 15 | 5 |
| Q2 2022 | 23 | 61 | 70 | 19 | 9 |
| Q3 2022 | 59 | 63 | 59 | 18 | 6 |
Hedge funds changes in Catalyst Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 108,000 | 128,000 |
|---|---|---|
| Q1 2018 | 60,000 | 78,000 |
| Q2 2018 | 293,000 | 79,000 |
| Q3 2018 | 928,000 | 458,000 |
| Q4 2018 | 32,000 | 113,000 |
| Q1 2019 | 683,000 | 1,188,000 |
| Q2 2019 | 981,000 | 1,714,000 |
| Q3 2019 | 377,000 | 1,085,000 |
| Q4 2019 | 70,000 | 340,000 |
| Q1 2020 | 819,000 | 239,000 |
| Q2 2020 | 1,010,000 | 134,000 |
| Q3 2020 | 827,000 | 297,000 |
| Q4 2020 | 233,000 | 313,000 |
| Q1 2021 | 834,000 | 272,000 |
| Q2 2021 | 634,000 | 2,573,000 |
| Q3 2021 | 491,000 | 1,113,000 |
| Q4 2021 | 261,000 | 6,000 |
| Q1 2022 | 550,000 | 454,000 |
| Q2 2022 | 715,000 | 141,000 |
| Q3 2022 | 1,884,000 | 1,432,000 |